Exco InTouch announced that it has successfully undergone and completed an independent audit to assess compliance utilizing the National Institute of Standards and Technology guidelines for Health Insurance Portability and Accountability Act security.
Exco InTouch, the leading provider of patient engagement and data capture solutions for clinical research and healthcare providers, today announced that it has successfully undergone and completed an independent audit to assess compliance utilizing the National Institute of Standards and Technology (NIST) guidelines for Health Insurance Portability and Accountability Act (HIPAA) security.
HIPAA rules constitute a set of regulations from the US Department of Health & Human Services relating to any Protected Health Information (PHI) that identifies health or financial data of US citizens stored on computer systems. The Security Rule specifies a series of administrative, physical, and technical safeguards for covered entities and their business associates to use to assure the confidentiality, integrity, and availability of electronic PHI.
Dale Jessop, Chief Technology Officer at Exco InTouch commented “Security of data and the protection of personal information remain the highest priority for Exco InTouch. Whilst no formal certification for HIPAA exists, to be independently audited against NIST guidelines for HIPAA security provides further reassurance to our customers that Exco InTouch business operations are aligned to comply with HIPAA standards.”
Tim Davis, CEO and co-founder of Exco InTouch added “I am extremely proud of the team involved throughout the audit process, and also that of the 64 HIPAA citations we were audited on, no findings were reported". As a result of this audit, Exco InTouch customers (for whom the company provides mobile and digital patient engagement solutions), can continue to be assured that their programs comply with these stringent security safeguards.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.